Loading...
 
Back to the list
Mediterr J Rheumatol 2019;30(Supp 1):76-81
Article Links
Biosimilars in the management of chronic inflammatory diseases: The Dutch experience
Wieland D. Müskens1, Sanne A. A. Rongen-van Dartel1,2, Eddy M. M. Adang3, Piet L. C. M. van Riel1,2
Authors Information

1Department of IQ Healthcare, Radboudumc, Nijmegen, The Netherlands
2Department of Rheumatology, Bernhoven, Uden, The Netherlands
3Department of Health Evidence, Radboudumc, Nijmegen, The Netherlands

Keywords: Biosimilars, nocebo-effect, switching, biologicals, non-medical switch
References
  1. The Dutch Medicines Board Opinion on Biosimilars, (2015).
  2. Standpunt Biosimilars Federatie Medisch Specialisten, (2017).
  3. Monitor geneesmiddelen in de medisch-specialistische zorg: Nederlandse Zorgautoriteit; 2017 [Available from: https://www.rijksoverheid.nl/documenten/rapporten/2017/12/21/monitor-geneesmiddelen-in-de-medisch-specialistische-zorg]
  4. Zorggids RN. Patent op reumamedicijn verlopen: prijs met 80 procent omlaag 2018 [Available from: https://www.nationalezorggids.nl/zorgverzekering/nieuws/45912-patent-op-reumamedicijn-verlopen-prijs-met-80-procent-omlaag.html]
  5. Glintborg B, Loft AG, Omerovic E, Hendricks O, Linauskas A, Espesen J, et al. To switch or not to switch: results of a nationwide guideline of mandatory switching from originator to biosimilar etanercept. One-year treatment outcomes in 2061 patients with inflammatory arthritis from the DANBIO registry. Ann Rheum Dis 2019;78(2):192-200. [https://doi.org/10.1136/annrheumdis-2018-213474] [PMID: 30396903]
  6. Scherlinger M, Langlois E, Germain V, Schaeverbeke T. Acceptance rate and sociological factors involved in the switch from originator to biosimilar etanercept (SB4). Semin Arthritis Rheum 2019;48(5):927-32. [https://doi.org/10.1016/j.semarthrit.2018.07.005] [PMID: 30093238]
  7. Tweehuysen L, Huiskes VJB, van den Bemt BJF, Vriezekolk JE, Teerenstra S, van den Hoogen FHJ, et al. Open-Label, Non-Mandatory Transitioning From Originator Etanercept to Biosimilar SB4: Six-Month Results From a Controlled Cohort Study. Arthritis Rheumatol  2018;70(9):1408-18. [https://doi.org/10.1002/art.40516] [PMID: 29609207]
  8. Odinet JS, Day CE, Cruz JL, Heindel GA. The Biosimilar Nocebo Effect? A Systematic Review of Double-Blinded Versus Open-Label Studies. J Manag Care Spec Pharm 2018;24(10):952-9. [https://doi.org/10.18553/jmcp.2018.24.10.952] [PMID: 30247100]
  9. Kravvariti E, Kitas GD, Mitsikostas DD, Sfikakis PP. Nocebos in rheumatology: emerging concepts and their implications for clinical practice. Nat Rev Rheumatol 2018;14(12):727-40. [https://doi.org/10.1038/s41584-018-0110-9] [PMID: 30361674]
  10. Faasse K, Petrie KJ. The nocebo effect: patient expectations and medication side effects. Postgrad Med J 2013;89(1055):540-6. [https://doi.org/10.1136/postgradmedj-2012-131730] [PMID: 23842213]
  11. Rezk MF, Pieper B. Treatment Outcomes with Biosimilars: Be Aware of the Nocebo Effect. Rheumatol Ther 2017;4(2):209-18. [https://doi.org/10.1007/s40744-017-0085-z] [PMID: 29032452] [PMCID: PMC5696297]
  12. Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, et al. Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent. BioDrugs 2018;32(5):397-404. [https://doi.org/10.1007/s40259-018-0306-1] [PMID: 30269270] [PMCID: PMC6182448]
  13. Wiland P, Batko B, Brzosko M, Kucharz EJ, Samborski W, Swierkot J, et al. Biosimilar switching - current state of knowledge. Reumatologia 2018;56(4):234-42. [https://doi.org/10.5114/reum.2018.77975] [PMID: 30237628] [PMCID: PMC6142020]
  14. Kay J, Schoels MM, Dorner T, Emery P, Kvien TK, Smolen JS, et al. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis 2018;77(2):165-74. [https://doi.org/10.1136/annrheumdis-2017-211937] [PMID: 28866648]
  15. Monitor Contractering en inkoop geneesmiddelen in de medisch specialistische zorg. 2016.
  16. Smits LJ, Derikx LA, de Jong DJ, Boshuizen RS, van Esch AA, Drenth JP, et al. Clinical Outcomes Following a Switch from Remicade® to the Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: A Prospective Observational Cohort Study. J Crohns Colitis 2016;10(11):1287-93. [https://doi.org/10.1093/ecco-jcc/jjw087] [PMID: 27095751]
  17. Smits LJT, Grelack A, Derikx L, de Jong DJ, van Esch AAJ, Boshuizen RS, et al. Long-Term Clinical Outcomes After Switching from Remicade® to Biosimilar CT-P13 in Inflammatory Bowel Disease. Dig Dis Sci 2017;62(11):3117-22. [https://doi.org/10.1093/ecco-jcc/jjw087] [PMID: 27095751]
  18. Smits LJT, van Esch AAJ, Derikx L, Boshuizen R, de Jong DJ, Drenth JPH, et al. Drug Survival and Immunogenicity After Switching From Remicade to Biosimilar CT-P13 in Inflammatory Bowel Disease Patients: Two-year Follow-up of a Prospective Observational Cohort Study. Inflamm Bowel Dis 2019;25(1):172-9. [https://doi.org/10.1093/ibd/izy227] [PMID: 29947795]
  19. Schmitz EMH, Boekema PJ, Straathof JWA, van Renswouw DC, Brunsveld L, Scharnhorst V, et al. Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12-month multicentre observational prospective cohort study. Aliment Pharmacol Ther 2018;47(3):356-63. [https://doi.org/10.1111/apt.14453] [PMID: 29205444]
  20. Layegh Z, Ruwaard J, Hebing RCF, MJ LA, van der Weele W, Nurmohamed MT, et al. Efficacious transition from reference infliximab to biosimilar infliximab in clinical practice. Int J Rheum Dis 2019;22(5):869-73. [https://doi.org/10.1111/1756-185X.13512] [PMID: 30767391]
  21. Federatie Medisch Specialisten, NVZA. Toolbox Biosimilars Een praktische handleiding voor succesvolle implementatie van biosimilars in de medisch specialistische zorg. 2017 april 2017.
  22. Boone NW, Liu L, Romberg-Camps MJ, Duijsens L, Houwen C, van der Kuy PHM, et al. The nocebo effect challenges the non-medical infliximab switch in practice. Eur J Clin Pharmacol 2018;74(5):655-61. [https://doi.org/10.1007/s00228-018-2418-4] [PMID: 29368188] [PMCID: PMC5893662]
  23. Müskens WD, Rongen-van Dartel SAA, Adang E, van Riel PL. AB0475 The influence of switching from etanercept originator to its biosimilar on effectiveness and and the impact of shared decision making on retention and withdrawal rates. Ann Rheum Dis 2018;77:1399.
  24. Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Subjective Complaints as the Main Reason for Biosimilar Discontinuation After Open-Label Transition From Reference Infliximab to Biosimilar Infliximab. Arthritis Rheum 2018;70(1):60-8. [https://doi.org/10.1002/art.40324] [PMID: 29045077]
  25. Binkhorst L, Sobels A, Stuyt R, Westerman EM, West RL. Short article: Switching to a infliximab biosimilar: short-term results of clinical monitoring in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2018;30(7):699-703. [https://doi.org/10.1097/MEG.0000000000001113] [PMID: 29538037]
  26. Jacobs IA, Singh E, Sewell KL, Al-Sabbagh A, Shane LG. Patient Understanding and Attitudes About Biosimilars: An International Cross-Sectional Survey. Value Health 2015;18(7):A680. [https://doi.org/10.1016/j.jval.2015.09.2022] [PMID: 26533813]
  27. Gulacsi L, Brodszky V, Baji P, Kim H, Kim SY, Cho YY, et al. Biosimilars for the management of rheumatoid arthritis: economic considerations. Expert Rev Clin Immunol 2015;11 Suppl 1:S43-52. [https://doi.org/10.1586/1744666X.2015.1090313] [PMID: 26395836]
  28. Jha A, Upton A, Dunlop WC, Akehurst R. The Budget Impact of Biosimilar Infliximab (Remsima®) for the Treatment of Autoimmune Diseases in Five European Countries. Adv Ther 2015;32(8):742-56. [https://doi.org/10.1007/s12325-015-0233-1] [PMID: 26343027] [PMCID: PMC4569679]
  29. Liu Y, Garg V, Yang M, Wu EQ, Skup M. AB1276 Economic impact of non-medical switching from originator biologics to biosimilars – a systematic literature review. Ann Rheum Dis 2018;77:1731-2.
  30. Longfonds R, Crohn-Colitis Ulcerosa Vereniging Nederland, Harteraad, Nederlandse Hypofyse Stichting, Dutch Brain Council, Epilepsie Vereniging Nederland, Hoofdpijnnet, Nationale Vereniging ReumaZorg Nederland,Nierpatiënten Vereniging Nederland, Patiëntenfederatie Nederland, Samenwerkende oogpatiëntenorganisaties, Schildklier organisatie Nederland, Vereniging Nederland Davos. Gevolgen van generieke geneesmiddelsubstitutie voor mensen met een chronische aandoening en Aanbevelingen voor de aanpak van knelpunten. 2018.